Perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients

Clinical Infectious Diseases

Volumn 47, Issue 5, 2008, Pages 702-711

  Torres Madriz, Gilberto ^a,b   Boucher, Helen W ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; GW 1263W94; GW 275175X; LEFLUNOMIDE; TOMEGLOVIR; VALACICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; CYTOSINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ANAPHYLAXIS; ANEMIA; ARTICLE; ASEPTIC MENINGITIS; BONE MARROW TOXICITY; CHILL; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEADACHE; HEMOLYSIS; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; KIDNEY FAILURE; LIVER TOXICITY; LUNG EDEMA; MAINTENANCE THERAPY; MENTAL HEALTH; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEINURIA; RASH; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TUBULAR DYSFUNCTION; UREMIA; ANTIVIRAL RESISTANCE; CHEMOPROPHYLAXIS; IMMUNE DEFICIENCY; METHODOLOGY; REVIEW; TRANSPLANTATION;

ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DRUG RESISTANCE, VIRAL; FOSCARNET; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION; PHOSPHONIC ACIDS; TRANSPLANTATION;

EID: 49449098166     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/590934     Document Type: Article

References (94)

1. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261:3607-9.
2. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741-51.
3. Snydman DR. Infection in solid organ transplantation. Transpl Infect Dis 1999; 1:21-8.
4. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007; 21:149-58.
5. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32:742-51.
6. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006; 16:281-7.
7. Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005; 40:709-12.
8. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006; 16:289-95.
9. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335:721-9.
10. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Research 2006; 71:154-63.
11. Crumpacker C, Marlowe S, Zhang JL, Abrams S, Watkins P. Treatment of cytomegalovirus pneumonia. Rev Infect Dis 1988; 10(Suppl 3):S538-46.
12. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185:854-60.
13. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356:645-9.
14. West P, Schmiedeskamp M, Neeley H, Oberholzer J, Benedetti E, Kaplan B. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transpl Infect Dis 2007; 129-32.
15. Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65:859-78.
16. Luan FL, Chopra P, Park J, Norman S, Cibrik D, Ojo A. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients. Transplant Proc 2006; 38:3673-5.
17. Fellay J, Venetz J-P, Pacual M, Aubert J-D, Seudoux C, Meylan PRA. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Am J Transplant 2005; 5:1781-2.
18. Babel N, Gabdrakhmanova L, Juergensen J-S, et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 2004; 78:283-5.
19. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79:85-90.
20. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5:1462-8.
21. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6:2134-43.
22. Razonable RR, Emery VC; 11th Annual Meeting of the IHMF (International Herpes Management Forum). Management of CMV infection and disease in transplant patients: 27-29 February 2004. Herpes 2004; 11:77-86.
23. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001; 3(Suppl 2):20-4.
24. Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97:388-92.
25. Chakrabarti S, Collingham KE, Osman H, Fegan CD, Milligan DW. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001; 28:879-81.
26. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5:218-27 (erratum: Am J Transplant 2005; 5:635).
27. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001; 72:1647-52.
28. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4:1635-42.
29. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109:777-82.
30. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109:783-8.
31. Zamora MR, Davis RD, Leonard C; Committee CMVABE. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005; 80:157-63 (erratum: Transplantation 2005; 80:545).
32. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8:158-61.
33. Snydman DR. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 2001; 3(Suppl 2):6-13.
34. George MJ, Snydman DR, Werner BG, et al. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG-Study Group. Transplant Proc 1993; 25:22-4.
35. American Society of Transplantation. Guidelines for the prevention and management of infectious complications of solid organ transplantation: cytomegalovirus. Am J Transplant 2004; 4(Suppl 10):51-8.
36. Len O, Gavalda J, Aguado J, et al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 2008; 46:20-7.
37. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106-13.
38. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1997; 25:314-7.
39. Humar A, Paya C, Pescovitz MD, et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004; 4:644-9.
40. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181:717-20.
41. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40:704-8 (erratum: Clin Infect Dis 2005; 40:1214).
42. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33:E62-8.
43. Slifkin M, Ruthazer R, Freeman R, et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 2005; 11:1597-602.
44. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
45. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326:1182-6.
46. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8:69-77.
47. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomized controlled trials. Lancet 2005; 365:2105-15.
48. Strippoli GFM, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81:139-45.
49. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870-80.
50. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43:869-80.
51. Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81:1106-11.
52. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811-5.
53. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006; 12:112-6 (erratum: Liver Transpl 2006; 12:494).
54. Weng FL, Patel AM, Wanchoo R, et al. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007; 83:290-6.
55. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79:1477-83.
56. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119:984-91.
57. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317:1049-54.
58. Hodson EM, Barclay PG, Craig JC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2005:CD003774.
59. Snydman DR, Falagas ME, Avery R, et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 2001; 33:2571-5.
60. Sagedal S, Nordal KP, Hartmann A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18:1899-908.
61. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006; 35:474-7.
62. Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 2002; 4:189-94.
63. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873-83.
64. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32:596-603.
65. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7:166-70 (erratum: Transpl Infect Dis 2006; 8:58).
66. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189:1615-8.
67. Simmons P, Kaushansky K, Torok-Storb B. Mechanisms of cytomegalovirus-mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci U S A 1990; 87:1386-90.
68. Randolph-Habecker J, Iwata M, Torok-Storb B. Cytomegalovirus mediated myelosuppression. J Clin Virol 2002; 25(Suppl 2):S51-6.
69. Patel HD, Anderson JR, Duncombe AS, Carrington D, Murday A. Granulocyte colony-stimulating factor: a new application for cytomegalovirus-induced neutropenia in cardiac allograft recipients. Transplantation 1994; 58:863-7.
70. Squiers EC, Elkhammas EA, Henry ML. Use of granulocyte-macrophage colony-stimulating factor for reversal of neutropenia following combined kidney-pancreas transplantation. Transplant Proc 1995; 27:3092-3.
71. Sulecki M, Rosenfeld CS, Przepiorka D, Bloom EJ, Buhles W Jr, Shadduck RK. Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF. Am J Med 1991; 90:401-2.
72. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263w94, a benzimidazole l-riboside with a unique mode of action. Antimicrob Agents Chemother 2002; 46:2365-72.
73. Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002; 46:2969-76.
74. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263w94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003; 47:1334-42.
75. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37:124-7.
76. National Institutes of Health. A randomized, double-blind study to assess the efficacy and safety of prophylactic use of maribavir versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00497796?term=maribavir&rank=2. Accessed 7 December 2007.
77. Underwood MR, Ferris RG, Selleseth DW, et al. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob Agents Chemother 2004; 48:1647-51.
78. Reefschlaeger J, Bender W, Hallenberger S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001; 48:757-67.
79. McSharry JJ, McDonough A, Olson B, et al. Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob Agents Chemother 2001; 45:2925-7.
80. Wan WB, Beadle JR, Hartline C, et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 2005; 49:656-62.
81. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003; 59:163-71.
82. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002; 46:2381-6.
83. Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6:69-75.
84. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73:358-66.
85. John GT, Manivannan J, Chandy S, Peter S, Jacob CK. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 2004; 77:1460-1.
86. John GT, Manivannan J, Chandy S, et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005; 37:4303-5.
87. Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8:38-43.
88. Battiwalla M, Paplham P, Almyroudis NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis 2007; 9:28-32.
89. Maribavir, 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263. Drugs R D 2007; 8:188-92.
90. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004; 39:233-9.
91. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med 1991; 114:525-31.
92. Heineman TC, Schleiss M, Bernstein DI, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006; 193:1350-60.
93. Vilalta A, Mahajan RK, Hartikka J, et al. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther 2005; 16:1143-50.
94. Pepperl-Klindworth S, Frankenberg N, Plachter B. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J Clin Virol 2002; 25(Suppl 2):S75-85.